- Cytomegalovirus (CMV) retinitis in HIV-infected patients
- Available as 75 mg/mL non-preserved solution in 5 mL vial
- Diluted solutions stable 24 hours refrigerated or room temperature
-Solution Compatible: NS, D5W
-Additives/Above Cassette Compatible: no information
-Y-site Compatible: no information
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
|IV Intermittent Infusion||
YES Large Volume Pump only. Don't use a minibag smaller than 50 mL
Usual dilution: 3 mg/mL
Patient fluid restricted: 8 mg/mL
Infusion time: 60 minutes
|IV Continuous Infusion||NO|
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
Pediatric and Adult dose:
- Induction : 5 mg/kg/dose IV once weekly x 2
- Maintenance: 5 mg/kg/dose IV every second week
Reduce dose in renal dysfunction (CrCl < 55 ml/min). Discontinue cidofovir if serum creatinine increases greater than 44 umol/L or > 3+ proteinuria.
Administration of cidofovir must be accompanied by concomitant oral probenecid & IV NS hydration:
1. Probenecid orally (Use multiple of 1/4 tab of 500 mg tab):
- 3 hours pre-dose - 25 mg/kg/dose up to 2 g .
- 2 & 8 hours post-dose (after end of infusion) - 12.5 mg/kg/dose up to 1 g
Using the "Dissolve and Dose" device, dissolve 250 to 500 mg in 10 mL. It takes approximately 10 minutes to dissolve with vigorous shaking. For nasogastric tubes, flush with approximately 10 mL before and after each dose.
2. IV Hydration: NS 10 -15 mL/kg up to 1 L over 1-3 hours pre-dose
NS 10 -15 mL/kg up to 1 L over 1-2 hours post-dose (if tolerated)
Dose-limiting: renal toxicity
Increase in serum creatinine > 130 umol/L (18%), >1+ proteinuria (80%), decreased intraocular pressure (24%), anterior uveitis/iritis (11%), nausea and vomiting (65%), fever (57%), decreased wbc (ANC<0.75 31% ANC<0.5 20%), headache (27%), diarrhea (27%), alopecia (25%), infections (25%), chills (24%), dyspnea (22%), anemia (20%), abdominal pain (17%), metabolic acidosis (Fanconi's syndrome) (2%)
Probenecid: rash, dyspepsia, allergic phenomena (48%) (can be more serious than cidofovir?s ADR
(Caution with sulfonamide allergy)
Prior to each dose: creatinine , BUN, WBC with diffferential, urine protein.
Periodically: electrolytes (calcium, magnesium, phosphorus), uric acid, SPOT/SGPT, Intraocular pressure, visual acuity